Granic A, Hill TR, Kirkwood TBL, Davies K, Collerton J, Martin-Ruiz C, von Zglinicki T, Saxby BK, Wesnes KA, Collerton D, Mathers JC, Jagger C.

Serum 25-hydroxyvitamin D and cognitive decline in the very old: The Newcastle 85+ study.

European Journal of Neurology 2015, 22(1), 106-e7.

Copyright:

© 2014 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Link to published article:

http://dx.doi.org/10.1111/ene.12539

Date deposited:

17/04/2015

This work is licensed under a Creative Commons Attribution 3.0 Unported License

Newcastle University ePrints - eprint.ncl.ac.uk
Serum 25-hydroxyvitamin D and cognitive decline in the very old: the Newcastle 85+ Study

A. Granica, T. R. Hillb,c, T. B. L. Kirkwoodb, K. Daviesa, J. Collertonb, C. Martin-Ruizb, T. von Zglinickib, B. K. Saxbya, K. A. Wesnesde, D. Collertonf, J. C. Mathsab and C. Jaggera

*Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne; bHuman Nutrition Research Centre, Newcastle University, Newcastle upon Tyne; cSchool of Agriculture, Food and Rural Development, Newcastle University, Newcastle upon Tyne; dWesnes Cognition Ltd, Streatley-on-Thames; eDepartment of Psychology, Northumbria University, Newcastle upon Tyne; and fInstitute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK

Keywords: attention, cognitive decline, cohort study

25-hydroxyvitamin D

Received 4 February 2014
Accepted 23 January 2014

European Journal of Neurology 2015, 22: 106–115
doi:10.1111/ene.12539

Background and purpose: Studies investigating the association between 25-hydroxyvitamin D [25(OH)D] and cognition in the very old (85+) are lacking.

Methods: Cross-sectional (baseline) and prospective data (up to 3 years follow-up) from 775 participants in the Newcastle 85+ Study were analysed for global (measured by the Standardized Mini-Mental State Examination) and attention-specific (measured by the attention battery of the Cognitive Drug Research test) cognitive performance in relation to season-specific 25(OH)D quartiles.

Results: Those in the lowest and highest season-specific 25(OH)D quartiles had an increased risk of impaired prevalent (1.66, 95% confidence interval 1.06–2.60, \(P = 0.03\); 1.62, 95% confidence interval 1.02–2.59, \(P = 0.04\), respectively) but not incident global cognitive functioning or decline in functioning compared with those in the middle quartiles adjusted for sociodemographic, health and lifestyle confounders. Random effects models showed that participants belonging to the lowest and highest 25(OH)D quartiles, compared with those in the middle quartiles, had overall slower (log-transformed) attention reaction times for Choice Reaction Time (lowest, \(\beta = 0.023\), \(P = 0.01\); highest, \(\beta = 0.021\), \(P = 0.02\)), Digit Vigilance Task (lowest, \(\beta = 0.009\), \(P = 0.05\); highest, \(\beta = 0.01\), \(P = 0.02\)) and Power of Attention (lowest, \(\beta = 0.017\), \(P = 0.02\); highest, \(\beta = 0.022\), \(P = 0.002\)) and greater Reaction Time Variability (lowest, \(\beta = 0.021\), \(P = 0.02\); highest, \(\beta = 0.02\), \(P = 0.03\)). The increased risk of worse global cognition and attention amongst those in the highest quartile was not observed in non-users of vitamin D supplements/medication.

Conclusion: Low and high season-specific 25(OH)D quartiles were associated with prevalent cognitive impairment and poorer overall performance in attention-specific tasks over 3 years in the very old, but not with global cognitive decline or incident impairment.

Introduction

Recent evidence from life sciences and epidemiology points to the role of serum 25-hydroxyvitamin D [25(OH)D] in brain function, including cognition, across the life span [1,2]. Detection of hydroxylases for vitamin D activation and vitamin D receptors in neurons and glia in brain regions essential for cognition and memory implicates their relevance for brain health. Moreover, in vitro and in vivo studies propose neuroprotective properties of 25(OH)D [2].

Current epidemiological research suggests an inverse or non-linear (i.e. curvilinear or U-shaped) association between circulating 25(OH)D concentration and risk
of several age-related chronic diseases and all-cause mortality [3–8], suggesting beneficial health outcomes at moderate (~50–60 nM) or higher concentrations (~75–80 nM). Based on skeletal health [7], it has been estimated that 50 nM (20 ng/ml) of 25(OH)D meets the requirements of >97.5% of the US population across all age groups. However, a number of studies have demonstrated a high prevalence of 25(OH)D inadequacy amongst older adults based on a clinical threshold of 25 or 30 nM [9,10]. A higher risk of low vitamin D status (<25 nM) in older adults has been linked to reduced epidermal stores of 7-dehydrocholesterol (vitamin D precursor), immobility, malnutrition, renal impairment and environmental factors [10,11]. However, current scientific evidence is inadequate to allow the development of recommendations for optimal age-specific 25(OH)D concentrations, or clinical thresholds, for extra-skeletal health in older adulthood. There is also uncertainty about the utility of vitamin D supplementation, especially for those aged 75+ living with comorbidities [7,11,12]. Although recent evidence indicates that supplementation improves vitamin D status in older adults without adversely affecting health and survival [13], there is no consensus on the definition of hypovitaminosis D and upper 25(OH)D thresholds for optimum physical and mental health in old age to prevent problems with under- or over-treatment [7,11,12,14].

Non-optimal concentration of 25(OH)D, variously defined as <25 nM (10 ng/ml) or <50 nM (20 ng/ml), has been implicated as a risk factor for global cognitive impairment [15,16] and weaker performance on domain-specific cognitive tasks [17–20] in several, but not all, cross-sectional studies [21] involving adults aged 60+. Only four prospective studies reported an increased risk of cognitive decline in association with lower concentrations of serum 25(OH)D (≤50 nM) in adults aged 65+ [22–25]. Studies on 25(OH)D and cognitive decline in those aged 85+ are scarce [26,27]. The Newcastle 85+ Study was therefore used to test for the presence of either an inverse or a non-linear association between 25(OH)D concentrations and cognition at baseline and cognitive decline over 3 years, utilizing measures of global and attention-specific cognitive function.

Method

Participants

Participants were drawn from the Newcastle 85+ Study, a longitudinal study of health trajectories and outcomes in a single-year birth cohort (1921) recruited from general practices in Newcastle and North Tyneside, UK, as described elsewhere [28,29]. The study was approved by the Newcastle and North Tyneside Local Research Committee One. At baseline (2006–2007), both multidimensional health assessment and general practice records data were available for 845 individuals who formed the basis for this analysis. Serum 25(OH)D was successfully measured from blood samples in 775 (91.7%) individuals [30]. Participants were followed up at 1.5 and 3 years.

Cognitive assessments

Global cognitive function was evaluated using the Standardized Mini-Mental State Examination (SMMSE), a brief dementia-screening instrument which provides a global score of cognitive function ranging from 0 to 30 points [31] that correlates well with performance in activities of daily living [31,32]. In all, 773 (91.5%) participants with a baseline SMMSE score and 25(OH)D status formed our analytical sample (Fig. S1). Cognitive status was defined as normal (SMMSE scores ≥26) or impaired (SMMSE scores ≤25) [31,32] at baseline and 3-year follow-up. Incident cognitive impairment was defined as crossing the 25-point threshold of the SMMSE [32]. Models in which cognitive decline was defined as a loss of ≥3 points from the baseline score (i.e. clinically meaningful or reliable change) [33,34] were also considered.

Attention was measured using the attention subsets of the Cognitive Drug Research (CDR) computerized assessment system [35,36] (see Method S1 for details), comprising mean reaction times (speed scores) of correct responses (in ms) for Simple Reaction Time (SRT), Choice Reaction Time (CRT) and Digit Vigilance Task (DVT). SRT measures alertness and concentration; CRT examines similar abilities including the extra time taken to discriminate between two opposing stimuli (i.e. reflecting the additional information processing in this task); and DVT tests sustained attention whilst ignoring distractors. Additionally three validated composite measures derived from these tasks were used: Power of Attention (PoA), a sum of the three attention speed scores, measures the intensity of concentration and the ability to focus attention [37]; Reaction Time Variability (RTV), a sum of coefficients of variance of the three speed scores, measures fluctuation in attention [38,39]; and Continuity of Attention (CoA), a combination of the accuracy scores from CRT and DVT, assesses the ability to sustain attention over the testing period [39]. Details of how composite measures were constructed and their validation process are described in Method S1. For all attention-specific measures except CoA, lower scores indicate better performance. A total of 761 participants had at least...
one attention task score at baseline. A training session 1 week prior to baseline measurements was undertaken with 91.5% (n = 773) of participants [40].

**Serum 25(OH)D assay**

Serum 25(OH)D was obtained from fasting morning blood samples and measured by the DiaSorin Radioimmune Assay kit as described [30] (see Method S2 for details). The mean (SD) time between cognitive testing and blood sampling was 0.28 (0.59) months. Because of seasonal variation in 25(OH)D concentration [41], the season of blood draw [December–February (Winter), March–May (Spring), June–August (Summer), and September–November (Autumn)] was controlled for by creating season-specific quartiles (SQ1–SQ4) [42] with cut-offs of 5–17 nM (Spring) to 8–20 nM (Autumn) for SQ1, 18–26 nM (Spring) to 29–45 nM (Summer) for SQ2, 27–46 nM (Spring) to 46–68 nM (Summer) for SQ3 and ≥47 nM (Spring) to ≥69 nM (Summer) for SQ4 (for details see Method S3). The middle quartiles (SQ2 and SQ3) were combined and used as the referent, thus generating three season-specific 25(OH)D groups: lowest, middle and highest.

**Other measures/confounders**

Confounders used in the above reported studies [16,22,23,25] were considered for inclusion in the models (see Method S4 for details). Briefly, sociodemographic factors (sex, education, income), health and morbidity [individual chronic diseases: cardiovascular diseases (includes hypertension, cardiac disease and peripheral vascular disease), cerebrovascular diseases, diabetes, osteoporosis; or total number of chronic diseases, renal impairment, depression, waist–hip ratio, serum vitamin B₁₂ and folate), and lifestyle factors (smoking, alcohol and physical activity) were included. Because the intake of supplements and medication containing vitamin D was regarded as an important biological determinant of 25(OH)D status in this population, separate analyses were conducted with the entire cohort and with a ‘restricted cohort’ (i.e. excluding 167 (19.8%) individuals who were taking vitamin D supplements/medication).

**Statistical analysis**

Participants (n = 845) were compared across the three season-specific 25(OH)D groups by Kruskal–Wallis tests for ordered and non-normally distributed continuous variables and χ² tests for categorical variables. For several confounders, missing values were imputed to the reference value to allow for comparison of nested models. Several logistic regression models were fitted to explore the association between season-specific 25(OH)D groups and prevalent cognitive impairment (odds ratio, 95% confidence interval). Models were unadjusted (model 1), adjusted for sex and education (model 2) and adjusted for all confounders (model 3). The models were then fitted with incident cognitive impairment defined as converting from normal to impaired cognitive status at 3-year follow-up. Cognitive status 3 years post baseline was also examined, and cognitive decline of ≥3 points as an outcome was used to determine a clinically meaningful/reliable change in the SMMSE [33,34].

All attention reaction times were converted into seconds and logarithmically (log₁₀) transformed to correct a positive skew, and to aid convergence. PoA and RTV were also log₁₀ transformed, whereas CoA was negatively skewed and corrected as \( \text{NEWX} = \sqrt{\frac{K}{C_0}} \) in which \( K = \text{maximum score} + 1 \). Using all available data for 845 participants, multilevel linear modelling [43] was conducted to determine the effect of 25(OH)D on initial level and rate of change over 3 years in attention-specific tasks, and a series of linear growth curve models were fitted as follows: (i) with ‘time’ in the study (to examine the linear trend of time) and season-specific 25(OH)D groups [to test whether initial status (intercept) varied by 25(OH)D] (model 1); (ii) with an interaction of season-specific 25(OH)D groups and time [to test for varying rates of change by 25(OH)D] (model 2); and (iii) with further adjustment for confounders associated with cognition and 25(OH)D levels (model 3). The SPSS MIXED procedure (SPSS, IBM Corporation, Armonk, NY, USA), with restricted maximum likelihood method and autoregressive error covariance matrix was used to generate parameter estimates (\( \beta \)) for effects.

A number of sensitivity analyses of the 25(OH)D groups in relation to cognitive outcomes were undertaken. The analyses were repeated defining cognitive change as scoring –1 SD and –1.5 SD below the mean and using ≥3 SMMSE points for cognitive impairment (Method S5). The analyses were also repeated excluding participants with a diagnosis of dementia, and whether findings were due to terminal drop was explored.

**Results**

**Baseline characteristics of the participants by 25(OH)D groups**

Participants in the middle season-specific 25(OH)D group (SQ2 and SQ3 combined) were the least
depressed and the most physically active, whilst those in the highest quartile (SQ4) were more likely to be female, to take prescribed vitamin D, to have osteoporosis, and to have the highest levels of serum folate compared with participants in the other groups (Table S1). Compared with the middle group, those belonging to the lowest (SQ1) and/or highest (SQ4) season-specific 25(OH)D groups had more cognitive impairment (≤25 SMMSE score) \((H_2) = 26.55, \ P < 0.001\) and had worse reaction times on DVT \((H_2) = 8.91, \ P = 0.01\), PoA \((H_2) = 8.74, \ P = 0.01\), RTV \((H_2) = 7.73, \ P = 0.02\) and CoA \((H_2) = 10.51, \ P = 0.005\) (Table 1).

### 25(OH)D and prevalent global cognitive impairment (SMMSE)

Of 773 participants with baseline cognitive and 25(OH)D status used in the logistic regression models at baseline \((n = 839)\), follow-up at 1.5 years \((n = 286)\), and follow-up at 3 years \((n = 248)\), those lost to follow-up \((n = 470)\), those lost to follow-up

### Table 1

| Cognitive domain/scores | All participants | Lowest season-specific 25(OH)D group | Middle season-specific 25(OH)D group | Highest season-specific 25(OH)D group | \(P\) value\(^c\) |
|-------------------------|-----------------|-------------------------------------|-------------------------------------|-------------------------------------|----------------|
| **Cognitive status by SMMSE** | | | | | |
| Baseline (\(n\)) | 839 | 191 | 392 | 190 | |
| Total SMMSE (mean, SD) | 25.9 (5.3) | 25.0 (5.9) | 27.0 (3.6) | 25.4 (5.9) | <0.001 |
| Impaired (≤25 SMMSE score \(%, n\)) | 28.6 (240) | 37.7 (72) | 19.4 (36) | 33.7 (64) | <0.001 |
| Normal (26–30) | 71.4 (599) | 62.3 (119) | 80.6 (316) | 66.3 (126) | |
| Follow-up at 3 years (\(n\)) | 470 | 101 | 248 | 103 | |
| Total SMMSE (mean, SD) | 25.4 (5.5) | 24.0 (6.4) | 26.1 (4.6) | 25.4 (5.6) | 0.005 |
| Impaired (≤25 SMMSE score \(%, n\)) | 34.0 (160) | 47.5 (48) | 29.8 (74) | 30.1 (31) | 0.004 |
| Normal (26–30) | 66.0 (310) | 52.5 (53) | 70.2 (174) | 69.9 (72) | |
| **CDR Attention Battery** | | | | | |
| baseline (\(n\)) | 761 | 177 | 373 | 176 | |
| SRT (ms, mean, SD) | 475.4 (488.0) | 509.1 (540.6) | 459.5 (548.4) | 470.1 (234.7) | |
| CRT (ms, mean, SD) | 650.6 (350.7) | 687.6 (360.6) | 623.0 (340.6) | 658.0 (251.6) | |
| DVT (ms, mean, SD) | 526.0 (69.9) | 534.8 (73.0) | 518.5 (65.5) | 535.5 (76.0) | 0.01 |
| PoA (ms, mean, SD) | 1618.3 (583.7) | 1700.4 (846.1) | 1549.4 (337.6) | 1663.4 (490.2) | 0.01 |
| RTV (ms, mean, SD) | 64.3 (19.9) | 66.7 (21.5) | 62.7 (19.2) | 65.3 (20.1) | 0.02 |
| CoA (ms, mean, SD) | 51.4 (9.6) | 50.3 (9.7) | 52.4 (8.4) | 51.6 (10.3) | 0.005 |
| Follow-up at 1.5 years (\(n\)) | 570 | 127 | 284 | 130 | |
| SRT (ms, mean, SD) | 491.4 (314.1) | 500.4 (315.0) | 471.5 (290.3) | 517.3 (357.6) | |
| CRT (ms, mean, SD) | 669.0 (311.5) | 698.1 (317.8) | 642.4 (290.3) | 681.3 (268.7) | 0.03 |
| DVT (ms, mean, SD) | 532.7 (73.8) | 541.9 (70.1) | 528.2 (70.7) | 532.4 (80.5) | |
| PoA (ms, mean, SD) | 1691.7 (622.6) | 1738.4 (653.4) | 1642.1 (563.6) | 1727.3 (624.0) | |
| RTV (ms, mean, SD) | 64.4 (21.7) | 66.7 (24.7) | 62.1 (18.0) | 65.6 (23.4) | 0.02 |
| CoA (ms, mean, SD) | 51.6 (8.5) | 50.3 (9.8) | 52.2 (7.4) | 52.3 (8.1) | 0.005 |
| Follow-up at 3 years (\(n\)) | 416 | 87 | 222 | 92 | |
| SRT (ms, mean, SD) | 475.3 (251.4) | 509.5 (303.8) | 454.6 (181.9) | 498.1 (339.1) | |
| CRT (ms, mean, SD) | 677.9 (368.9) | 727.4 (445.2) | 649.2 (327.1) | 709.2 (403.6) | |
| DVT (ms, mean, SD) | 533.8 (73.6) | 540.8 (69.9) | 531.9 (72.5) | 531.7 (80.9) | |
| PoA (ms, mean, SD) | 1687.5 (620.8) | 1777.9 (754.7) | 1635.6 (510.5) | 1741.3 (745.2) | |
| RTV (ms, mean, SD) | 63.4 (21.1) | 62.2 (17.9) | 62.6 (21.8) | 65.2 (21.5) | |
| CoA (ms, mean, SD) | 51.7 (8.7) | 51.5 (7.7) | 52.1 (8.2) | 51.9 (9.5) | |

SMMSE, Standardized Mini-Mental State Examination; CDR, cognitive drug research; SRT, simple reaction time; CRT, choice reaction time; DVT, digit vigilance task; PoA, power of attention. \(^a\)Untransformed scores; \(^b\)season-specific quartiles were derived for each season of blood draw and combined to create season-specific 25(OH)D groups (SQ1–SQ4); middle quartiles were collapsed (SQ2 and SQ3) and served as a reference; \(^c\)Kruskal–Wallis test for ordered and non-normally distributed continuous variables; \(^d\)RTV, reaction time variability, expressed as coefficient of variation; \(^e\)CoA, continuity of attention, expressed in CoA arbitrary units.
Table 2. Association between season-specific 25(OH)D groups and odds of prevalent cognitive impairment (OR, 95% CI)

| Season-specific 25(OH)D group | Model 1 | Model 2 | Model 3 |
|-------------------------------|---------|---------|---------|
| Lowest                        | 2.52 (1.71–3.70) | 1.66 (1.06–2.60) | 1.63 (1.02–2.59) |
| Middle                        | 2.42 (1.64–3.57) | 1.59 (1.02–2.50) | 1.33 (0.75–2.32) |
| Highest                       | 2.11 (1.43–3.12) | 1.63 (1.02–2.37) | 1.32 (0.75–2.32) |

OR, odds ratio; CI, confidence interval. Model 1 is unadjusted; model 2 is adjusted for sex and years of education; model 3 is additionally adjusted for number of income sources, smoking status, current alcohol consumption, waist-to-hip ratio, cardiovascular diseases (hypertension, cardiac disease, peripheral vascular diseases), cerebrovascular diseases, diabetes, osteoporosis, renal impairment, depressive symptoms and physical activity. The following missing variables were imputed to the reference value: education (n = 11, ref. ≤ 9 years), number of income sources (n = 5, ref. ≥ 6), smoking status (n = 2, ref. never smoker), alcohol consumption (n = 4, ref. no), renal impairment (n = 1, ref. no), depressive symptoms (n = 9, ref. no depressive symptoms) and physical activity (n = 6, ref. ≤ 1 SD or ≤ 1.0 SD or ≤ 1.5 SD below the mean using a 23-point cut-off to define cognitive impairment, as continuous outcome (i.e. difference scores), or when analyses were additionally controlled for vital status (dead or alive 2 years after the 3-year follow-up) to exclude possible terminal decline (data not shown).

25(OH)D and attention (CDR attention battery)

The associations between season-specific 25(OH)D groups and attention reaction times and attention-specific composite scores at baseline and at 1.5- and 3-year follow-ups were examined through multilevel models. All attention-specific reaction times (including information processing speed) showed a significant increase over 3 years (i.e. slower or poorer performance) after adjustment for potential confounders (Table 4). The linear growth rate for SRT, CRT, DVT and PoA reaction times increased (slowed) significantly by 0.028, 0.021, 0.009 and 0.023 log-transformed (mean) seconds per unit of time, respectively (Table 4, model 3). CoA (sustained attention) declined over time (i.e. negative β estimates in models with untransformed scores; data not shown). No linear time trend level was evident [n = 375 (44.4%); of whom 360 died and 15 did not complete the follow-up SMMSE] had fewer sources of retirement income (P = 0.02), were less physically active (P < 0.001), had more depressive symptoms (P = 0.007) and chronic diseases (P = 0.006), and were more likely to be cognitively impaired at baseline (P < 0.001). Participants who remained in the study were more likely to take other vitamin supplements (P = 0.001) but not prescribed vitamin D medication (P = 0.001) and were more likely to drink alcohol (P < 0.001). The groups did not differ on serum 25(OH)D status (P = 0.94).
Table 3: Association between season-specific 25(OH)D groups and odds of incident impairment 3 years later

| Season-specific 25(OH)D group | Entire cohort, n = 452 | Participants not taking vitamin D supplements/medication, n = 380 | Model 1 | Model 2 | Model 3 |
|------------------------------|------------------------|-----------------------------------------------------------------|---------|---------|---------|
| Lowest                       | 0.98 (0.55–1.75)       | 0.98 (0.55–1.75)                                                 | 0.31    | 0.31    | 0.31    |
| Middle                       | 1.06 (0.61–2.00)       | 0.94                                                             | 0.37    | 0.37    | 0.37    |
| Highest                      | 1.62 (0.31–9.23)       | 1.82                                                             | 0.22    | 0.22    | 0.22    |

OR, odds ratio; CI, confidence interval. Model 1 is unadjusted; model 2 is adjusted for sex and years of education; model 3 is additionally adjusted for number of income sources, smoking status (not current smoker), number of chronic conditions (model 3), both the lowest and highest quartiles of 25(OH)D were associated with overall slower reaction times and information processing speed in CRT and DVT and with increased PoA (i.e. focused attention/intensity of concentration) and RTV scores (i.e. greater fluctuation in attention) compared with the middle quartile. The log-transformed means of DVT sustained attention speed were slower by 0.009 s (P = 0.05) and by 0.010 s (P = 0.002) for participants belonging to the lowest and highest 25(OH)D quartiles, respectively. The log-transformed RTV coefficients of variance were higher by 0.021 (P = 0.02) for those in the lowest quartile and by 0.020 (P = 0.03) for participants in the highest 25(OH)D quartile, indicating greater fluctuation in attention compared with participants in the middle 25(OH)D group. A significant effect of highest 25(OH)D quartile on PoA [β (SE) = 0.022 (0.007), P = 0.002] but not on CoA (P = 0.14) was also observed, suggesting that the overall change in PoA speed amongst these participants was independent of the poorer ability to sustain attention/accuracy. A non-significant time by 25(OH)D group interaction for all outcomes and models indicated that the slopes (rate of change) did not vary by 25(OH)D quartile between individuals over the study period (Table 4). In the 'restricted cohort', similar conclusions regarding 25(OH)D and attention-specific outcomes held for the lowest but not the highest 25(OH)D group (Table S3).

Discussion

In this prospective, population-based study of older adults aged 85+, it was found that both low and high season-specific quartiles of 25(OH)D were associated with higher odds of prevalent cognitive impairment (assessed by SMMSE), poorer attention reaction times/processing speed and focused attention/concentration, and greater attention fluctuation (assessed by CDR). Differences remained significant after adjustment for sex, education, lifestyle factors and the presence of several chronic diseases, although effects were small. In the fully adjusted model the harmful effect of the highest season-specific 25(OH)D quartile on focused attention (PoA) seemed to be independent of the ability to sustain attention/accuracy (CoA), suggesting no concentration–accuracy trade-offs. How-
Table 4 Parameter estimates\(^a\) of growth curve models for attention tasks over 3 years by season-specific 25(OH)D groups\(^b\) (entire cohort)

| Outcome | Effects | Model 1 | Model 2 | Model 3 |
|---------|---------|---------|---------|---------|
|         |         | \(\beta\) (SE) | \(P\) | \(\beta\) (SE) | \(P\) | \(\beta\) (SE) | \(P\) |
| SRT     | Intercept | 0.029 (0.005) | <0.001 | 0.028 (0.007) | <0.001 | 0.028 (0.007) | <0.001 |
|         | 25(OH)D  | Lowest | 0.031 (0.011) | 0.006 | 0.030 (0.012) | 0.009 | 0.02 (0.012) | 0.09 |
|         |         | Middle (ref.) | 0.0 | 0.0 | 0.0 | 0.0 |
|         |         | Highest | 0.025 (0.011) | 0.03 | 0.025 (0.012) | 0.03 | 0.023 (0.012) | 0.05 |
| Slope   | 25(OH)D × time (n/a) | Lowest × time | 0.004 (0.013) | 0.75 | 0.004 (0.013) | 0.74 | 0.02 (0.012) | 0.09 |
|         |         | Middle × time (ref.) | 0.0 | 0.0 | 0.0 | 0.0 |
|         |         | Highest × time | −0.002 (0.013) | 0.90 | −0.002 (0.012) | 0.85 |
| CRT     | Intercept | 0.025 (0.004) | <0.001 | 0.021 (0.006) | <0.001 | 0.021 (0.006) | <0.001 |
|         | 25(OH)D  | Lowest | 0.032 (0.009) | 0.001 | 0.031 (0.009) | 0.001 | 0.023 (0.009) | 0.01 |
|         |         | Middle (ref.) | 0.0 | 0.0 | 0.0 | 0.0 |
|         |         | Highest | 0.026 (0.009) | 0.006 | 0.025 (0.009) | 0.007 | 0.021 (0.009) | 0.02 |
| Slope   | 25(OH)D × time (n/a) | Lowest × time | 0.005 (0.010) | 0.65 | 0.007 (0.010) | 0.48 | 0.007 (0.010) | 0.48 |
|         |         | Middle × time (ref.) | 0.0 | 0.0 | 0.0 | 0.0 |
|         |         | Highest × time | 0.009 (0.010) | 0.38 | 0.007 (0.012) | 0.47 |
| DVT     | Intercept | 0.079 (0.002) | <0.001 | 0.008 (0.003) | <0.001 | 0.009 (0.004) | <0.001 |
|         | 25(OH)D  | Lowest | 0.014 (0.004) | 0.002 | 0.013 (0.004) | 0.004 | 0.009 (0.004) | 0.05 |
|         |         | Middle (ref.) | 0.0 | 0.0 | 0.0 | 0.0 |
|         |         | Highest | 0.011 (0.004) | 0.006 | 0.012 (0.004) | 0.004 | 0.010 (0.004) | 0.02 |
| Slope   | 25(OH)D × time (n/a) | Lowest × time | 0.002 (0.005) | 0.61 | 0.002 (0.005) | 0.66 | 0.002 (0.005) | 0.66 |
|         |         | Middle × time (ref.) | 0.0 | 0.0 | 0.0 | 0.0 |
|         |         | Highest × time | −0.004 (0.005) | 0.39 | −0.004 (0.005) | 0.34 |
| PoA     | Intercept | 0.026 (0.003) | <0.001 | 0.023 (0.005) | <0.001 | 0.023 (0.004) | <0.001 |
|         | 25(OH)D  | Lowest | 0.024 (0.007) | 0.001 | 0.025 (0.007) | 0.001 | 0.017 (0.007) | 0.02 |
|         |         | Middle (ref.) | 0.0 | 0.0 | 0.0 | 0.0 |
|         |         | Highest | 0.026 (0.007) | <0.001 | 0.026 (0.007) | <0.001 | 0.022 (0.007) | 0.02 |
| Slope   | 25(OH)D × time (n/a) | Lowest × time | 0.009 (0.008) | 0.27 | 0.009 (0.008) | 0.27 | 0.009 (0.008) | 0.27 |
|         |         | Middle × time (ref.) | 0.003 (0.008) | 0.71 | 0.003 (0.008) | 0.71 | 0.003 (0.008) | 0.71 |
|         |         | Highest × time | 0.003 (0.008) | 0.71 | 0.003 (0.008) | 0.71 | 0.003 (0.008) | 0.71 |
| RTV     | Intercept | 0.003 (0.004) | 0.43 | 0.004 (0.005) | 0.46 | 0.005 (0.005) | 0.38 |
|         | 25(OH)D  | Lowest | 0.024 (0.008) | 0.003 | 0.03 (0.009) | 0.003 | 0.021 (0.009) | 0.02 |
|         |         | Middle (ref.) | 0.0 | 0.0 | 0.0 | 0.0 |
|         |         | Highest | 0.018 (0.008) | 0.03 | 0.017 (0.009) | 0.06 | 0.020 (0.009) | 0.03 |
| Slope   | 25(OH)D × time (n/a) | Lowest × time | −0.007 (0.01) | 0.48 | −0.005 (0.01) | 0.61 | −0.005 (0.01) | 0.61 |
|         |         | Middle × time (ref.) | 0.0 | 0.0 | 0.0 | 0.0 |
|         |         | Highest × time | 0.003 (0.009) | 0.78 | 0.002 (0.009) | 0.80 | 0.002 (0.009) | 0.80 |
| CoA     | Intercept | 0.091 (0.041) | 0.03 | 0.107 (0.056) | 0.06 | 0.122 (0.054) | 0.03 |
|         | 25(OH)D  | Lowest | 0.313 (0.087) | <0.001 | 0.325 (0.093) | 0.001 | 0.294 (0.092) | 0.001 |
|         |         | Middle (ref.) | 0.0 | 0.0 | 0.0 | 0.0 |
|         |         | Highest | 0.029 (0.087) | 0.74 | 0.039 (0.093) | 0.68 | 0.134 (0.092) | 0.14 |
| Slope   | 25(OH)D × time (n/a) | Lowest × time | −0.038 (0.104) | 0.71 | −0.030 (0.10) | 0.77 | −0.030 (0.10) | 0.77 |
|         |         | Middle × time (ref.) | 0.0 | 0.0 | 0.0 | 0.0 |
|         |         | Highest × time | −0.033 (0.102) | 0.75 | −0.040 (0.098) | 0.68 | −0.040 (0.098) | 0.68 |

SRT, simple reaction time; CRT, choice reaction time; DVT, digit vigilance task; PoA, power of attention; RTV, reaction time variability; CoA, continuity of attention. Model 1 includes serum 25(OH)D and linear trend of time; in model 2 a linear trend of time by serum 25(OH)D interaction is added; model 3 is further adjusted for education, sex, smoking status, current alcohol intake, renal impairment and number of chronic diseases (0–1 diseases, 0; two diseases, 1; three and more diseases, 2). \(^a\)Estimated \(\beta\) values (SE) of fixed effects using transformed longitudinal data for all outcomes. Random effects terms included both intercept and slopes of attention scores over time. Time in the study was coded as baseline (0), 1.5-year follow-up (1) and 3-year follow-up (2). \(^b\)Serum 25(OH)D was categorized in season-specific quartiles. Middle quartiles (SQ2 and SQ3) were combined and served as the reference group.
ever, the rate of change of all attention measures did not vary across 25(OH)D groups, and no association between 25(OH)D and odds of global incident cognitive impairment or decline was found. In analyses restricted to vitamin D supplements/medication non-users, only the associations with the lowest season-specific 25(OH)D group remained for both global cognitive and attention-specific outcomes.

To our knowledge, this is the first prospective study to find evidence for a U-shaped relationship between 25(OH)D and global cognitive function and attention in the very old. Taken together, it could be hypothesized that the neuroprotective effects of vitamin D mediated via expression of proteins that, for example, attenuate the toxicity of reactive oxygen species [44] in very old neurons are attained only at moderate but not at low or high 25(OH)D concentrations.

Thus far, only four prospective studies of older adults aged 65+ have examined the association between 25(OH)D and prevalent and incident global cognitive impairment, and decline in attention and executive function, with inconsistent results. A study of community-dwelling older men [22] found limited evidence of an independent association between lower 25(OH)D concentration (≤19.9 ng/ml) and incident cognitive impairment or decline in global and executive function. A similar study involving community-dwelling older women [23] reported that very low (<25 nM) and low levels (<50 nM) of 25(OH)D were associated with an increased risk of impaired global cognitive function and decline [defined by modified MMSE (3MS)], but not with impaired executive function or decline. Two further studies have also investigated these 25(OH)D cut-points. The InCHIANTI study found that compared with participants with sufficient 25(OH)D (≥75 nM) the deficient group (<25 nM) experienced a substantial global (assessed by MMSE) and executive cognitive decline (assessed by Trails A and B) over 6 years [24], whilst the Health, Aging and Body Composition Study confirmed that lower 25(OH)D (<50 nM) was associated with a greater cognitive decline on the 3MS compared with sufficient 25(OH)D (≥75 nM) over 4-year follow-up [25].

A similar global cognitive measure as in previous studies was utilized, although different serum 25(OH)D cut-offs were derived a posteriori [42], but no association between 25(OH)D and global incident impairment or decline after adjustment for confounders was detected. This lack of association may be due to the age of our participants, reduced power to detect the association, specific definition of cognitive change at an individual level, and/or changed serum 25(OH)D status over the 3 years of the study. Increased mortality amongst older women belonging to the lowest and highest season-specific 25(OH)D quartiles as observed in this cohort [45] could be one of the reasons for the loss of analytical power. Incident impairment was defined as crossing the 25-point threshold of SMMSE [31,32]. Although only five participants converted from cognitively normal to impaired by losing one point, a loss of <3 points may not represent a true change at an individual level.

Reported adverse effects of higher 25(OH)D appeared to be driven by those taking prescribed vitamin D medication [n = 139 (16.5%)] who may have had prior (long-standing) vitamin D deficiency. Therefore, a potential negative effect of the highest 25(OH)D quartile on cognitive functioning could be partly driven by those with chronic vitamin D inadequacy who through supplementation reached higher concentrations shortly before baseline assessments. Nonetheless our finding is in agreement with reports from the NHANES III, a cross-sectional study of the non-institutionalized US population, aged 60–90 years, where the worst performance on learning and memory tasks was associated with the highest quintile of 25(OH)D [21]. The Institute of Medicine Committee (2011) [7] emphasized a curvilinear association between 25(OH)D and non-skeletal health outcomes (e.g. all-cause mortality, cancers, cardiovascular diseases) and cautioned against the assumption that higher 25(OH)D concentrations (>50 nM) inevitably provide greater health benefits. This has been confirmed by a large retrospective study that included older adults aged 75+ from Copenhagen general practices, which found the lowest risk of all-cause mortality over 3 years was associated with 50–60 nM of 25(OH)D [6].

About 27% of participants scored <26 SMMSE points at baseline. There is therefore the possibility of reverse causation (i.e. non-optimal 25(OH)D concentrations being a consequence of prevalent cognitive impairment) [46], although excluding those with dementia diagnosis in sensitivity analyses (n = 57) did not change the U-shaped association between vitamin D groups and baseline cognitive impairment after adjusting for covariates (lowest, odds ratio 1.89, 95% confidence interval 1.18–3.03, P = 0.008; highest, 1.82, 1.11–2.97, P = 0.02; data not shown).

To assess change in attention/information processing speed, attention fluctuation and accuracy in relation to 25(OH)D, the CDR system, previously used in dementia studies and clinical trials to discriminate between various types of dementias and to detect change in attention-specific cognitive domains pre and post treatment with millisecond precision, was employed [36,37,47]. Specifically, focused attention (PoA) showed a clinically meaningful decline of 59 ms over 6 months in very mildly impaired Alzheimer's
disease patients (MMSE >26) taking cholinesterase inhibitors [48]. In the present study, participants in the lowest and highest season-specific 25(OH)D quartiles had overall worse focused attention and were by ~96 ms and ~86 ms slower (mean of raw scores), respectively, than those in the middle group at 18 months' follow-up. Future studies will determine whether these attention deficits relate to decline in global cognition and interfere with daily functioning [49].

A small clinical trial of patients aged 65 and over with a history of falls and 25(OH)D insufficiency (≤12 ng/ml) showed an improvement of 0.4 s in CRT, compared with the control group, 6 months after a single intramuscular injection of vitamin D, which increased the average serum 25(OH)D from 10.4 to 17.5 ng/ml – the latter within the middle quartiles reported here to be associated with better attention scores [50]. There are some limitations of our study mainly related to loss to follow-up, use of a single measure of 25(OH)D and unknown 25(OH)D status prior to baseline assessments. Although participants remaining in the study had similar 25(OH)D concentrations to those lost to follow-up, they were less cognitively impaired and depressed, had fewer chronic diseases and were less likely to take prescribed vitamin D medication. In this cohort, prescribed vitamin D was a significant determinant of the highest, and less beneficial, serum 25(OH)D concentration. A single measurement of circulating 25(OH)D may inadequately reflect overall vitamin D status due to its cyclical nature [41], although a preferred statistical method was used to adjust for seasonal variability in 25(OH)D when only one sample was available [42]. Generalization of our findings may be limited to adults aged 85+ of white ethnicity living at similar latitudes (55°N). Lastly, observed statistically significant worse attention scores have limited interpretability and may not be clinically meaningful and warrant treatment or intervention.

The strengths of our study include (i) its prospective design, the representativeness of the cohort and inclusion of the institutionalized older adults who were assessed at residency to reduce attrition and selection bias [28,29]; (ii) the inclusion of several cognition-related covariates in multivariate analyses with the entire cohort and 'restricted cohort'; and (iii) implementation of global and attention-specific tests that were validated and pilot-tested in this age group [40].

In summary, it was observed that both low and high season-specific concentrations of 25(OH)D were associated with increased risk of prevalent cognitive impairment and worse attention-specific tasks amongst older adults aged 85+, although the rates of change were similar across vitamin D groups. Poorer cognitive functioning in participants belonging to the highest season-specific 25(OH)D group was driven by those receiving vitamin D supplements/medication. Future prospective studies should test the proposed U-shaped relationship between serum 25(OH)D and cognition in this age group and determine whether other cognitive domains are affected similarly by 25(OH)D status.

Acknowledgements

This work was supported by the National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust and Newcastle University (AG). The Newcastle 85+ Study has been funded by the Medical Research Council, Biotechnology and Biological Sciences Research Council and the Dunhill Medical Trust. Additional work has also been funded by the British Heart Foundation, Unilever Corporate Research, Newcastle University and National Health Service (NHS) North of Tyne (Newcastle Primary Care Trust). The views expressed in this paper are those of the authors and not necessarily those of the National Health Service, UK. We acknowledge the operational support of NHS North of Tyne, the local general practitioners and their staff, the research nurses, laboratory technicians, data management and clerical team, as well as many colleagues for their expert advice. Thanks are due especially to the study participants.

Disclosure of conflicts of interest

Dr Saxby is an ex-employee of Cognitive Drug Research (CDR) Ltd, a commercial provider of the CDR computerized system, now owned by Bracket Global, Goring-on-Thames, UK, which provides the CDR system to the clinical trials industry. Dr Wesnes, the inventor of the CDR system, is an ex-employee and stockholder of Bracket Global now employed by Wesnes Cognition Ltd, Streatley-on-Thames, UK. At the time of the Newcastle 85+ Study, the CDR was a proprietary system owned by Dr Wesnes, who provided it to the study on a non-commercial basis. Other than grants for the Newcastle 85+ Study, Dr Granic, Dr Hill, Dr Kirkwood, Dr Davies, Dr J. Collerton, Dr Martin-Ruiz, Dr von Zglinicki, Dr D. Collerton, Dr Mathers and Dr Jagger report no disclosures.

Supporting Information

Additional Supporting Information may be found in the online version of this article.
Method S1. Cognitive assessment.
Method S2. Serum 25(OH)D assay.
Method S3. Season-specific 25(OH)D quartile cut-offs.
Method S4. Description and coding of confounders used in logistic regression and growth models.
Method S5. Statistical analysis.
Figure S1. Newcastle 85+ Study participants by SMMSE scores and 25(OH)D status availability over the study period.

Table S1. Baseline characteristics of participants in the Newcastle 85+ Study by serum 25(OH)D.
Table S2. Association between season-specific 25(OH)D groups and odds of cognitive impairment (odds ratio, 95% confidence interval) at 3-year follow-up.
Table S3. Parameter estimates of growth curve models for attention tasks over 3 years by season-specific 25(OH)D groups (‘restricted cohort’).
References

1. Balion C, Griffith LE, Strifler L, et al. Vitamin D, cognition, and dementia. Neurology 2012; 79: 1397–1405.
2. Kesby JP, Eyles DW, Burne THJ, Burne THJ, McGrath JJ. The effects of vitamin D on brain development and adult brain function. Mol Cell Endocrinol 2011; 347: 121–127.
3. Wang L, Song Y, Manson JE, et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes 2012; 5: 819–829.
4. IARC. Vitamin D and Cancer. IARC Working Group Reports Vol. 3. Lyon, France: International Agency for Research on Cancer, 2008.
5. Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomized intervention studies. BMJ 2014; 348: g1903.
6. Durup D, Jørgensen HL, Christensen J, Schwarz P, Hegardt AM, Lind B. A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD Study. J Clin Endocrinol Metab 2012; 97: 2644–2652.
7. Institute of Medicine (IOM). Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press, 2011.
8. Dror Y, Giveon SM, Hoshen M, Feldhammer I, Balicer RD, Feldman BS. Vitamin D levels for preventing acute coronary syndrome and mortality: evidence of a nonlinear association. J Clin Endocrinol Metab 2013; 98: 2160–2167.
9. Hirani V, Primasteta P. Vitamin D concentrations among people aged 65 years and over living in private households and institutions in England: population study. Age Ageing 2005; 34: 485–491.
10. Overes L, Andersen R, Jakobsen J. Geographical differences in vitamin D status, with particular reference to European countries. Proc Nutr Soc 2003; 62: 813–821.
11. Holick MF. Vitamin D: a D-lightful health perspective. Nutr Rev 2008; 66: S182–S194.
12. Sanders KM, Nicholson GC, Ebeling PR. Is high dose vitamin D harmful? Calcif Tissue Int 2013; 92: 191–206.
13. Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2014; 1: CD007470.
14. Cranney A, Horsley T, O’Donnell S, et al. Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess (Full Rep) 2007; 158: 1–235.
15. Annweiler C, Schott AM, Allali G, et al. Association of vitamin D deficiency with cognitive impairment in older women: cross-sectional study. Neurology 2010; 74: 27–32.
16. Llewellyn DJ, Lang IA, Langa KM, Melzer D. Vitamin D and cognitive impairment in the elderly U.S. population. J Gerontol A Biol Sci Med Sci 2011; 66: 59–65.
17. Buell JS, Scott TM, Dawson-Hughes B, et al. Vitamin D is associated with cognitive function in elders receiving home health services. J Gerontol A Biol Sci Med Sci 2009; 64: 888–895.
18. Hansen AL, Dahl L, Bakke L, Thayer JF. Vitamin D and executive function: a preliminary report. Percept Mot Skills 2011; 113: 667–685.
19. Lee DM, Tajjar A, Ulubaev A, et al. Association between 25-hydroxyvitamin D levels and cognitive performance in middle-aged older European men. J Neurol Neurosurg Psychiatry 2009; 80: 722–729.
20. Saemans KM, Hill TR, Scully L, et al. Vitamin D status and measures of cognitive function in healthy older European adults. Eur J Clin Nutr 2010; 64: 1172–1178.
21. McGrath J, Scragg R, Chant D, Eyles D, Burne T, Oberdovic D. No association between serum 25-hydroxyvitamin D3 levels and performance on psychometric tests in NHANES III. Neuroepidemiology 2007; 29: 49–54.
22. Slinin Y, Paudel ML, Taylor BC, et al. 25-Hydroxvitamin D levels and cognitive performance and decline in elderly men. Neurology 2010; 74: 33–41.
23. Slinin Y, Paudel M, Taylor BC, et al. Association between serum 25(OH) vitamin D and the risk of cognitive decline in older women. J Gerontol A Biol Sci Med Sci 2012; 67: 1092–1098.
24. Llewellyn DJ, Lang IA, Langa KM, et al. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med 2010; 170: 1135–1141.
25. Wilson VK, Houston DK, Kilpatrick L, et al. Relationship between 25-hydroxyvitamin D and cognitive function in older adults: the health, aging and body composition study. J Am Geriatr Soc 2014; 62: 636–641.
26. Formiga F, Ferrer A, Almeda J, San Jose A, Gil A, Pujol R. Utility of geriatric assessment tools to identify 85-years old subjects with vitamin D deficiency. J Nutr Health Aging 2011; 15: 110–114.
27. Menant JC, Close JC, Delbaere K, et al. Relationship between serum vitamin D levels, neuromuscular and neuropsychological function and falls in older men and women. Osteoporos Int 2012; 23: 981–989.
28. Collerton J, Barras K, Bond J, et al. The Newcastle 85+ study: biological, clinical and psychological factors associated with healthy ageing: study protocol. BMC Geriatr 2007; 7: 14.
29. Collerton J, Davies K, Jagger C, et al. Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study. BMJ 2009; 399: b4904.
30. Martin-Ruiz C, Jagger C, Kingston A, et al. Assessment of a large panel of candidate biomarkers of ageing in the Newcastle 85+ Study. Mech Ageing Dev 2011; 132: 496–502.
31. Vertesi A, Lever JA, Molloy DW, et al. Standardized Mini-Mental State Examination. Can Fam Physician 2001; 47: 2018–2023.
32. Molloy DW, Standish T. A guide to standardize Mini-Mental State Examination. Int Psychogeriatr 1997; 9: 87–94.
33. Hensel A, Angermeyer MC, Riedel-Heller SG. Measuring cognitive change in older adults: reliable change indices for the Mini-Mental State Examination. J Neurol Neurosurg Psychiatry 2007; 78: 1298–1303.
34. Tomhaugh TN. Test-retest reliable coefficients and 5-year change scores for the MMSE and 3ME. Arch Clin Neuropsychol 2005; 20: 485–503.
35. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK. The cognitive drug research computerized assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 1991; 6: 95–102.
36. Wesnes KA. Assessing change in cognitive function in dementia: the relative utilities of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale and the Cognitive Drug Research System. Neurodegener Dis 2008; 5: 261–263.
37. Wesnes KA, Ward T, McGinty A, Petrioli O. The memory enhancing effects of a Ginko biloba/Panax ginseng combination in healthy middle-aged volunteers. *Psychopharmacology* 2000; **152**: 353–361.

38. Ballard CG, Aarsland D, McKeith I, *et al.* Fluctuations in attention. PD dementia vs DLB with parkinsonism. *Neurology* 2002; **59**: 1714–1720.

39. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. *Neurology* 2005; **65**: 1654–1656.

40. Collerton J, Collerton D, Arai Y, *et al.* A comparison of computerized and pencil-and-paper task in assessing cognitive function in community-dwelling older people in the Newcastle 85+ pilot study. *J Am Geriatr Soc* 2007; **55**: 1630–1635.

41. Shoben AB, Kestenbaum B, Levin G, *et al.* Seasonal variation in 25-hydroxyvitamin D concentrations in the Cardiovascular Health Study. *Am J Epidemiol* 2011; **174**: 1363–1372.

42. Wang Y, Jacobs EJ, McCullough ML, *et al.* Comparing methods for accounting for seasonal variability in a biomarker when only a single sample is available: insights from simulation based on serum 25-hydroxyvitamin D. *Am J Epidemiol* 2009; **170**: 88–94.

43. Singer JD, Willett JB. *Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence*, 1st edn. New York, NY: Oxford University Press, 2003.

44. Ibi M, Sawada H, Nakanishi M, *et al.* Protective effect of 1alpha,25-(OH)(2)D-3 against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. *Neuropharmacology* 2001; **40**: 761–771.

45. Granic A, Aspray T, Hill T, *et al.* 25-hydroxyvitamin D and increased all-cause mortality in the very old women: the Newcastle 85+ study. *J Intern Med* 2014; doi: 10.1111/joim.12273 [Epub ahead of print].

46. Johansson P, Almqvist EG, Johansson J-O, *et al.* Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer’s disease. *PLoS One* 2013; **8**: e81989.

47. Rowan E, McKeith IG, Saxby BK, *et al.* Effects of donepezil on central processing speed and attentional measures in Parkinson’s disease with dementia and dementia with Lewy bodies. *Dement Geriatr Cogn Disord* 2007; **23**: 161–167.

48. Wesnes K, Edgar C, Andreasen N, *et al.* Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer’s disease. *Acta Neurol Scand* 2010; **122**: 270–277.

49. Bronnick K, Ehrt U, Emre M, *et al.* Attention deficits affect activities of daily living in dementia associated with Parkinson’s disease. *J Neurol Neurosurg Psychiatry* 2006; **77**: 1136–1142.

50. Dhesi JK, Jackson SH, Bearne LM, *et al.* Vitamin D supplementation improves neuromuscular function in older people who fall. *Age Ageing* 2004; **33**: 589–595.